Compare SAVA & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAVA | DRIO |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.1M | 84.1M |
| IPO Year | N/A | N/A |
| Metric | SAVA | DRIO |
|---|---|---|
| Price | $2.13 | $11.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 772.9K | 18.2K |
| Earning Date | 03-02-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,732,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 7.29 |
| 52 Week Low | $1.15 | $5.94 |
| 52 Week High | $4.98 | $17.74 |
| Indicator | SAVA | DRIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 49.56 |
| Support Level | $2.04 | $10.00 |
| Resistance Level | $2.22 | $11.25 |
| Average True Range (ATR) | 0.11 | 0.70 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 62.86 | 65.14 |
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.